Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy

Table 1

Clinicopathological characteristics of the patients.

	Total	NLR < 4.14	NLR ≧ 4.14	value
	()	()	()
Age (years)
<65	11 (47.6%)	4 (44.4%)	7 (50.0%)	0.566
≥65	12 (52.4%)	5 (55.6%)	7 (50.0%)
Gender
Female	6 (26.1%)	4 (44.4%)	2 (14.3%)	0.131
Male	17 (73.9%)	5 (55.6%)	12 (85.7%)
Creatinine clearance (mL/min)
<60	3 (13.0%)	2 (22.2%)	1 (7.1%)	0.332
≥60	20 (87.0%)	7 (77.8%)	13 (92.9%)
Clinical lymph node metastasis
Yes	19 (82.6%)	8 (88.9%)	11 (78.6%)	0.483
No	4 (17.4%)	1 (11.1%)	3 (21.4%)
Neoadjuvant chemotherapy
Yes	4 (17.4%)	3 (33.3%)	1 (7.1%)	0.147
No	19 (82.6%)	6 (66.7%)	13 (92.9%)
Clinical T stage
≤2	6 (26.1%)	2 (22.2%)	4 (28.6%)	0.565
≥3	17 (73.9%)	7 (77.8%)	10 (71.4%)